Coronary imaging developer InfraReDx has raised $24.1 million from the sale of equity to existing company shareholders.
Proceeds from the financing will be used to expand manufacturing operations and commercial infrastructure. They will also be used for ongoing and new clinical trials investigating expanded clinical applications of the company's LipiScan intravascular ultrasound (IVUS) coronary imaging system.
The system includes a cardiac catheter to combine IVUS and near-infrared spectroscopy to help cardiologists identify and characterize plaques known to complicate stenting and suspected to cause most heart attacks, the firm said.
InfraReDx launched LipiScan in September 2010 after receiving clearance from the U.S. Food and Drug Administration (FDA).
